A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein

Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat advanced melanoma patients with B...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Liu, Juan, Xiao, Xiaojuan, Sun, Shuming, Zhang, Hui, Zhang, Yibin, Zhou, Weihua, Zhang, Bin, Roy, Mridul, Liu, Hong, Ye, Mao, Wang, Zi, Liu-Smith, Feng, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859286/
https://www.ncbi.nlm.nih.gov/pubmed/31726389
http://dx.doi.org/10.1016/j.omtn.2019.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859286/
https://www.ncbi.nlm.nih.gov/pubmed/31726389
http://dx.doi.org/10.1016/j.omtn.2019.10.005

Ejemplares similares